Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option
DOI:
https://doi.org/10.33448/rsd-v12i3.40502Keywords:
Sodium-Glucose Transporter 2 Inhibitors; Heart Failure; Efficacy.Abstract
Despite the therapeutic options currently available for Heart Failure (HF), this pathology is still responsible for high rates of morbidity and mortality in the population. Faced with these current therapeutic limitations, the development of studies to evaluate the effectiveness of new drugs in HF is justified, among them the sodium-glucose cotransporter type 2 (SGLT2) inhibitors. In this context, the objective of this work is to evaluate the benefits and limitations of SGLT2 inhibitors in the management of HF. The present study is an integrative literature review carried out from the PubMed and VHL databases. Seven randomized clinical studies controlled by placebo were analyzed, from which it was verified that SGLT2 inhibitors presented promising therapeutic effect, with cardioprotective and renoprotective action, in a broad spectrum of HF, reducing the risk of hospitalizations and deaths from causes cardiovascular effects, regardless of the presence or absence of DM2, in addition to being safe and well tolerated. Therefore, the use of SGLT2 inhibitors represents an additional effective and safe therapeutic alternative with the potential to modify the morbidity and mortality of HF.
References
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M. & Packer, M. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The new England journal of medicine, 385(16), 1451-61. 10.1056/NEJMoa2107038
Böhm, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J. & Packer, M. (2021). Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 78(13), 1337–48. https://doi.org/10.1016/j.jacc.2021.07.049
Braga, F. G. M., Ramires, F. J. A., Figueiredo, E. L., Neto, J. A. F., Silva, L. B., & Rassi, S. (2020). Tópicos Emergentes em Insuficiência Cardíaca: Nova Era do Tratamento Farmacológico. Arq Bras Cardiol, 115(5), 956-60. https://doi.org/10.36660/abc.20201106
Cardoso, J. S., Andrade, A., Brito, D., Ferreira, J., Fonseca, C., Peres, M., Francok, F., & Moura, B. (2021). SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction. Revista Portuguesa de Cardiologia (English Edition), 40(9), 687-693. http://dx.doi.org/10.1016/j.repce.2021.02.006
Docherty, K. F., Jhund, P. S., Claggett, B., Ferreira, J. P., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez F. A., Ponikowski. P., Sabatine, M. S., Sjöstrand, M., Solomon. S. D., & McMurray. J. J. V. (2021). Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 6(11), 1298-1305. 10.1001/jamacardio.2021.2632
Galvão, M. C. B., & Ricarte, I. L. M. (2020). Revisão sistemática da literatura: conceituação, produção e publicação. Logeion: Filosofia da informação, 6(1), 57-73. https://doi.org/10.21728/logeion.2019v6n1.p57-73
Lan, N. S. R., Fegan, P. G., Yeap, B. B., & Dwivedi, G. (2019). The effects of sodium‐glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC heart failure, 6(5), 927-935. https://DOI: 10.1002/ehf2.12505
Lara, R. A. M., Bessa, L. L. C., Silveira, A. V. D., Souza, I. G., Ferreira, G. F. S., Souza, G. P., & França, D. S. (2021). Análise epidemiológica da insuficiência cardíaca no brasil. Brazilian Medical Students Journal, 6(9), 1-8. 10.53843/bms.v6i9.224
Latorraca, C.O. C., Rodrigues, M., Pacheco, R. L., Martimbianco, A. L. C., & Riera, R. (2019). Busca em bases de dados eletrônicas da área da saúde: por onde começar. Revista Diagnóstico e Tratamento, 24(2), 59-63. https://docs.bvsalud.org/biblioref/2019/09/1015338/rdt_v24n2_59-63.pdf
Li, H. L., Lip, G. Y. H., Feng, Q., Fei, Y., Tse, Y. K., Wu, M., Ren, Q. W., Tse, H. F., Cheung, B. M. Y., & Yiu, K. H. (2021). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovascular Diabetology, 20(1), 1-13. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12933-021-01293-8
Martins, C. N. G., Bau, A. A., Silva, L. M., & Filho, O. R. C. (2021). Possíveis Mecanismos dos Inibidores de SGLT2 na Insuficiência Cardíaca. ABC Heart Fail Cardiomyop, 1(1), 33-43. https://doi.org/10.36660/abchf.20210007
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C. E., Chopra, V. K., Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., Howlett, J. G., Katova, T., Kitakaze, M., Ljungman, C. E. A., Merkely, B., Nicolau, J. C., Meara, E. O., Petrie M. C., Vinh, P. N., Schou, M., Tereshchenko, S., Verma, S., Held, C., DeMets, D. L., Docherty, K. F., Jhund, P. S., Bengtsson, O., Sjöstrand, M., & Langkilde, A. M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The new England journal of medicine, 381(21), 1995-2008. 10.1056/NEJMoa1911303
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., Lamba, S., Sharma, K., Khan, S. S., Chandra, L., Gordon, R. A., Ryan, J. J., Chaudhry, S. P., Joseph, S. M., Chow, C. H., Kanwar, M. K., Pursley, M., Siraj, E. S., Lewis, G. D., Clemson, B. S., Fong, M., & Kosiborod, M. N. (2021). The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 27(11), 1954–1960. https://doi.org/10.1038/s41591-021-01536-x
Sharma, N., Srivastav, A. K., & Samuel, A. J. (2020). Ensaio clínico randomizado: padrão ouro de desenhos experimentais - importância, vantagens, desvantagens e preconceitos. Rev Pesqui Fisioter, 10(3), 512-519. https://doi: 10.17267/2238-2704rpf.v10i3.3039
Sociedade Brasileira de Cardiologia (2018). Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol, 111(3), 436-539. 10.5935/abc.20180190
Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, 28(4), 809–813. https://doi.org/10.1038/s41591-022-01703-8
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D. J., Chopra, V., Chuquiure, E., Giannetti, N., Janssens, S,. Zhang, J., Juanatey, J. R. G., Kaul, S., Rocca, H. P. B. L., Merkely, B., Nicholls, S. J., Perrone, S., Pina, I., Ponikowski, P., Sattar, N., Senni, M., Seronde, M. F., Spinar, J., Squire, I., Taddei, S., Wanner, C., & Zannad, F. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The new England journal of medicine, 383(15), 1413-1424. 10.1056/NEJMoa2022190
Pereira, G. A. R., & Silva, L. B. (2022). Iron Deficiency in Heart Failure with Reduced Ejection Fraction: Pathophysiology, Diagnosis and Treatment. Arquivos brasileiros de cardiologia, 118(3), 646-654. https://doi:10.36660/abc.20201257
Pradhan, A., Vohra, S., Vishwakarma, P., & Sethi, R. (2019). Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care, 8(6), 1855-1862. 10.4103/jfmpc.jfmpc_232_19
Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J. & Ponikowski, P. (2022). The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature medicine, 28(3), 568–574. https://doi.org/10.1038/s41591-021-01659-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Marcilyo Max Bezerra Soares; Arllen Mara Caminha Luz; Jefferson Noronha Bezerra Silva; Leonardo Francisco da Silva Guimarães; Daniel Matos de Sousa; Edvaldo Lucas da Costa Silva; Italo Rossi Roseno Martins
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
